Expression and regulatory function of miRNA-182 in triple-negative breast cancer cells through its targeting of profilin 1

Tumor Biology

Volumn 34, Issue 3, 2013, Pages 1713-1722

  Liu, Hailing ^a   Wang, Yan ^a   Li, Xin ^a   Zhang, Yan Jun ^a   Li, Jie ^a   Zheng, Yi Qiong ^a   Liu, Mei ^a   Song, Xin ^a   Li, Xi Ru ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

MicroRNA 182; PFN1 gene; Triple negative breast cancer

Indexed keywords

MICRORNA 182; PROFILIN; PROFILIN I; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL FUNCTION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; FLOW CYTOMETRY; GENE; HUMAN; HUMAN TISSUE; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROFILIN 1 GENE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST CANCER; WESTERN BLOTTING;

EID: 84878710863     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0708-0     Document Type: Article

References (39)

1. Ishikawa T, Shimizu D, Kito A, Ota I, Sasaki T, Tanabe M, et al. Breast cancer manifested by hematologic disorders. J Thorac Dis. 2012;4(6):650-4.
2. Arnedos M, Weigelt B, Reis-Filho JS. Anti-HER2 therapies: when more is more. Transl Cancer Res. 2012;1(1):49-54.
3. Fausto P, Sandro B. Benefit of tamoxifen in estrogen receptor positive DCIS of the breast. Gland Surg. 2012;1(1):3-4.
4. Rashid OM, Takabe K. The evolution of the role of surgery in the management of breast cancer lung metastasis. J Thorac Dis. 2012;4(4):420-4.
5. Nakhlis F, Golshan M. Bevacizumab: where do we go from here in breast cancer? Transl Cancer Res. 2012;1(1):55-6.
6. Hartman AR, Kaldate RR, Sailer LM, Painter L, Grier CE, Endsley RR, et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer. 2012;118(11):2787-95.
7. Gholami S, Chen CH, Lou E, De Brot M, Fujisawa S, Chen NG, et al. Vaccinia Virus GLV-1h153 is effective in treating and preventing metastatic triple-negative breast cancer. Ann Surg. 2012;256(3):437-45.
8. Gelmon K, Dent R, Mackey JR, Laing K, McLeod D, Verma S. Targeting triple-negative breast cancer: optimising therapeutic outcomes. Ann Oncol. 2012;23(9):2223-34.
9. Patnaik SK, Mallick R, Yendamuri S. MicroRNAs and esophageal cancer. J Gastrointest Oncol. 2010;1(1):55-63.
10. Link A, Kupcinskas J, Wex T, Malfertheiner P. Macro-role of microRNA in gastric cancer. Dig Dis. 2012;30(3):255-67.
11. Santovito D, Mezzetti A, Cipollone F. MicroRNAs and atherosclerosis: new actors for an old movie. Nutr Metab Cardiovasc Dis. 2012;22(11):937-43.
12. Pasquinelli AE. MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet. 2012;13(4):271-82.
13. Ui-Tei K, Nishi K, Takahashi T, Nagasawa T. Thermodynamic control of small RNA-mediated gene silencing. Front Genet. 2012;3:101.
14. Yang JS, Maurin T, Lai EC. Functional parameters of dicer-independent microRNA biogenesis. RNA. 2012;18(5):945-57.
15. Chen J, Wang B. The roles of miRNA-143 in colon cancer and therapeutic implications. Transl Gastrointest Cancer. 2012;1(2):169-74.
16. Du L, Pertsemlidis A. microRNA regulation of cell viability and drug sensitivity in lung cancer. Expert Opin Biol Ther. 2012;12(9):1221-39.
17. Wall NR. Colorectal cancer screening using protected microRNAs. J Gastrointest Oncol. 2011;2(4):206-7.
18. Saus E, Soria V, Escaramis G, Vivarelli F, Crespo JM, Kagerbauer B, et al. Genetic variants and abnormal processing of pre-miR-182, a circadian clock modulator, in major depression patients with late insomnia. Hum Mol Genet. 2010;19(20):4017-25.
19. Cai Y, Yu X, Hu S, Yu J. A brief review on the mechanisms of miRNA regulation. Genomics Proteomics Bioinformatics. 2009;7(4):147-54.
20. Segura MF, Hanniford D, Menendez S, Reavie L, Zou X, Alvarez-Diaz S, et al. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci U S A. 2009;106(6):1814-9.
21. Santos A, Van Ree R. Profilins: mimickers of allergy or relevant allergens? Int Arch Allergy Immunol. 2011;155(3):191-204.
22. Gieni RS, Hendzel MJ. Actin dynamics and functions in the interphase nucleus: moving toward an understanding of nuclear polymeric actin. Biochem Cell Biol. 2009;87(1):283-306.
23. Rodriguez Faba O, Palou J. Predictive factors for recurrence progression and cancer specific survival in high-risk bladder cancer. Curr Opin Urol. 2012;22(5):415-20.
24. Qin XJ, Ling BX. Proteomic studies in breast cancer (Review). Oncol Lett. 2012;3(4):735-43.
25. Wei F, Xu J, Tang L, Shao J, Wang Y, Chen L, et al. p27(Kip1) V109G polymorphism and cancer risk: a systematic review and meta-analysis. Cancer Biother Radiopharm. 2012;27(10):665-71.
26. Wu Y, Sun WL, Feng JF. Antiangiogenic therapy in the management of breast cancer. Asia Pac J Clin Oncol. 2012. doi: 10.1111/j.1743-7563.2012.01569.x.
27. Thorsen SB, Obad S, Jensen NF, Stenvang J, Kauppinen S. The therapeutic potential of microRNAs in cancer. Cancer J. 2012;18(3):275-84.
28. Cortez MA, Welsh JW, Calin GA. Circulating microRNAs as noninvasive biomarkers in breast cancer. Recent Results Cancer Res. 2012;195:151-61.
29. Vira D, Basak SK, Veena MS, Wang MB, Batra RK, Srivatsan ES. Cancer stem cells, microRNAs, and therapeutic strategies including natural products. Cancer Metastasis Rev. 2012;31(3-4):733-51.
30. Guan P, Yin Z, Li X, Wu W, Zhou B. Meta-analysis of human lung cancer microRNA expression profiling studies comparing cancer tissues with normal tissues. J Exp Clin Cancer Res. 2012;31(1):54.
31. Liu Z, Liu J, Segura MF, Shao C, Lee P, Gong Y, et al. MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma. J Pathol. 2012;228(2):204-15.
32. Alshalalfa M, Bader GD, Goldenberg A, Morris Q, Alhajj R. Detecting microRNAs of high influence on protein functional interaction networks: a prostate cancer case study. BMC Syst Biol. 2012;6(1):112.
33. Weeraratne SD, Amani V, Teider N, Pierre-Francois J, Winter D, Kye MJ, et al. Pleiotropic effects of miR-183 96 182 converge to regulate cell survival, proliferation and migration in medulloblastoma. Acta Neuropathol. 2012;123(4):539-52.
34. Kong WQ, Bai R, Liu T, Cai CL, Liu M, Li X, et al. MicroRNA-182 targets cAMP-responsive element-binding protein 1 and suppresses cell growth in human gastric adenocarcinoma. FEBS J. 2012;279(7):1252-60.
35. Poell JB, van Haastert RJ, de Gunst T, Schultz IJ, Gommans WM, Verheul M, et al. A functional screen identifies specific microRNAs capable of inhibiting human melanoma cell viability. PLoS One. 2012;7(8):e43569.
36. Rawe VY, Payne C, Schatten G. Profilin and actin-related proteins regulate microfilament dynamics during early mammalian embryogenesis. Hum Reprod. 2006;21(5):1143-53.
37. Sagot I, Rodal AA, Moseley J, Goode BL, Pellman D. An actin nucleation mechanism mediated by Bni1 and profilin. Nat Cell Biol. 2002;4(8):626-31.
38. Wang D, Huang J, Hu Z. RNA helicase DDX5 regulates microRNA expression and contributes to cytoskeletal reorganization in basal breast cancer cells. Mol Cell Proteomics. 2012;11(2):M111 011932.
39. Zou L, Ding Z, Roy P. Profilin-1 overexpression inhibits proliferation of MDA-MB-231 breast cancer cells partly through p27kip1 upregulation. J Cell Physiol. 2010;223(3):623-9.